SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended
	Jul. 02, 2021 USD ($) $ / shares shares	May 13, 2021 USD ($)	Jul. 23, 2018 USD ($)	Oct. 19, 2017 USD ($)	Oct. 31, 2015	Mar. 31, 2022 USD ($) agreement $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares
Significant Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares						$ 0.001	$ 0.001
Gross proceeds							$ 8,575
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares						33,004,217	26,769,693
2021 Notes
Significant Accounting Policies [Line Items]
Interest rate (as a percent)							7.50%
2024 Notes
Significant Accounting Policies [Line Items]
Interest rate (as a percent)						7.50%
Maintain of Minimum Cash Balance						$ 7,500
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]
Significant Accounting Policies [Line Items]
Collaborative Arrangement Revenues Expenses Sharing Percentage					100.00%
Chiesi US Agreement and Chiesi Ex US Agreement [Member]
Significant Accounting Policies [Line Items]
Non-refundable Payment Receivable			$ 25,000	$ 25,000
Chiesi Agreements
Significant Accounting Policies [Line Items]
Performance obligation number | agreement						2
Chiesi US Agreement [Member]
Significant Accounting Policies [Line Items]
Additional Amounts Payable To Cover Development Costs			20,000
Maximum entitlement of development costs to cover per year			7,500
Additional amount payable for achievement of regulatory and commercial milestones			$ 760,000
Chiesi US Agreement [Member] | Minimum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage			15.00%
Chiesi US Agreement [Member] | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage			40.00%
Chiesi Ex US Agreement [Member]
Significant Accounting Policies [Line Items]
Additional Amounts Payable To Cover Development Costs				25,000
Maximum entitlement of development costs to cover per year				10,000
Additional amount payable for achievement of regulatory and commercial milestones				$ 320,000
Change in amount receivable for achievement of regulatory and commercial milestones		$ 25,000
Agreement Amendment Payment Receivable		$ 10,000
Chiesi Ex US Agreement [Member] | Minimum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage				15.00%
Chiesi Ex US Agreement [Member] | Maximum
Significant Accounting Policies [Line Items]
Payment On Net Sales Percentage				35.00%
ATM Shares
Significant Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares	$ 0.001
Sale of stock, maximum offering price	$ 20,000
Number of shares issued (in shares) | shares	3,296,123
Gross proceeds	$ 13,800